Literature DB >> 15105095

Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002.

Kimiko Ubukata1, Naoko Chiba, Keiko Hasegawa, Reiko Kobayashi, Satoshi Iwata, Keisuke Sunakawa.   

Abstract

The antibiotic susceptibilities, genotypes of penicillin (PEN)-binding protein genes (pbp), and serotype distributions of Streptococcus pneumoniae isolates from meningitis patients were investigated by a nationwide surveillance group in Japan between 1999 and 2002. We analyzed 146 isolates from children (</=17 years old) and 73 from adults (>/=18 years old). Isolates with or without abnormal pbp1a, pbp2x, or pbp2b genes identified by PCR were classified into six genotype patterns and 90% MIC (MIC(90)) values for PEN: (i) strains with three normal genes (17.2% of isolates; MIC(90), 0.031 micro g/ml); (ii) strains with abnormal pbp2x (22.1%, 0.063 micro g/ml); (iii) strains with abnormal pbp2b (1.0%, 0.125 micro g/ml); (iv) strains with abnormal pbp2x and pbp2b (7.4%, 0.25 micro g/ml); (v) strains with abnormal pbp1a and pbp2x (12.7%, 0.25 micro g/ml); and (vi) strains with three abnormal PBP genes (39.7%, 4 micro g/ml), which are termed genotypic PEN-resistant S. pneumoniae (gPRSP). Panipenem, a carbapenem, showed an excellent MIC(90) (0.125 micro g/ml) against gPRSP, followed by meropenem and vancomycin (0.5 micro g/ml), cefotaxime and ceftriaxone (1 micro g/ml), and ampicillin (4 micro g/ml). Strains of gPRSP were significantly more prevalent in children (45.2%) than in adults (27.4%). The most frequent serotypes were 6B, 19F, 23F, 6A, and 14 in children and 23F, 22, 3, 10, 6B, and 19F in adults. Serotypes 6B, 6A, 19F, 23F, and 14 predominated among gPRSP. In children, 7- and 11-valent pneumococcal conjugate vaccines would cover 76.2 and 81.3% of isolates, respectively, although coverage would be lower in adults (43.9 and 56.0%, respectively). These findings suggest the need for early introduction of pneumococcal conjugate vaccines and continuous bacteriological surveillance for meningitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105095      PMCID: PMC400554          DOI: 10.1128/AAC.48.5.1488-1494.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

Review 1.  Review of consensus reports on management of acute otitis media.

Authors:  J O Klein
Journal:  Pediatr Infect Dis J       Date:  1999-12       Impact factor: 2.129

Review 2.  Conjugate pneumococcal vaccine and antibiotic-resistant Streptococcus pneumoniae: herd immunity and reduction of otitis morbidity.

Authors:  R Dagan; D Fraser
Journal:  Pediatr Infect Dis J       Date:  2000-05       Impact factor: 2.129

3.  Diversity of substitutions within or adjacent to conserved amino acid motifs of penicillin-binding protein 2X in cephalosporin-resistant Streptococcus pneumoniae isolates.

Authors:  Y Asahi; Y Takeuchi; K Ubukata
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Antibiotic susceptibility and serotype distribution of Streptococcus pneumoniae causing meningitis in Italy, 1997-1999.

Authors:  A Pantosti; F D'Ambrosio; A Tarasi; S Recchia; G Orefici; P Mastrantonio
Journal:  Clin Infect Dis       Date:  2000-11-29       Impact factor: 9.079

5.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Authors:  S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards
Journal:  Pediatr Infect Dis J       Date:  2000-03       Impact factor: 2.129

6.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Authors:  W P Hausdorff; J Bryant; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

7.  Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Recomm Rep       Date:  2000-10-06

8.  Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996-1998.

Authors:  E Miller; P Waight; A Efstratiou; M Brisson; A Johnson; R George
Journal:  Acta Paediatr Suppl       Date:  2000-12

9.  Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine.

Authors:  S Zielen; I Bühring; N Strnad; J Reichenbach; D Hofmann
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

10.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media.

Authors:  J Eskola; T Kilpi; A Palmu; J Jokinen; J Haapakoski; E Herva; A Takala; H Käyhty; P Karma; R Kohberger; G Siber; P H Mäkelä
Journal:  N Engl J Med       Date:  2001-02-08       Impact factor: 91.245

View more
  13 in total

1.  Microbiology of Bartholin's gland abscess in Japan.

Authors:  Kaori Tanaka; Hiroshige Mikamo; Mochiyoshi Ninomiya; Teruhiko Tamaya; Koji Izumi; Kunihiko Ito; Kazukiyo Yamaoka; Kunitomo Watanabe
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

Review 2.  Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1 infection.

Authors:  Lumin Zhang; Zihai Li; Zhuang Wan; Andrew Kilby; J Michael Kilby; Wei Jiang
Journal:  Vaccine       Date:  2015-06-30       Impact factor: 3.641

3.  Pneumococcal surface protein A family types of Streptococcus pneumoniae from community-acquired pneumonia patients in Japan.

Authors:  Y Ito; M Osawa; R Isozumi; S Imai; I Ito; T Hirai; T Ishida; S Ichiyama; M Mishima
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10       Impact factor: 3.267

4.  Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections.

Authors:  Somay Yamagata Murayama; Chizuko Seki; Hiroshi Sakata; Katsuhiko Sunaoshi; Eiichi Nakayama; Satoshi Iwata; Keisuke Sunakawa; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2009-03-30       Impact factor: 5.191

5.  In vitro activities of oral cephem and telithromycin against clinical isolates of major respiratory pathogens in Japan.

Authors:  Atsuyuki Shimizu; Kazunori Maebashi; Masashi Niida; Takeshi Mikuniya; Muneo Hikida; Kimiko Ubukata
Journal:  J Korean Med Sci       Date:  2007-02       Impact factor: 2.153

6.  High carriage rate of high-level penicillin-resistant Streptococcus pneumoniae in a Taiwan kindergarten associated with a case of pneumococcal meningitis.

Authors:  Tsai-Ling Lauderdale; Wei Yang Lee; Ming Fang Cheng; I Fei Huang; Yu Chen Lin; Kai Sheng Hseih; I-Wen Huang; Christine C Chiou
Journal:  BMC Infect Dis       Date:  2005-11-01       Impact factor: 3.090

7.  Substitutions in penicillin-binding protein 1 in amoxicillin-resistant Helicobacter pylori strains isolated from Korean patients.

Authors:  Beom Jin Kim; Jae G Kim
Journal:  Gut Liver       Date:  2013-08-14       Impact factor: 4.519

8.  Antimicrobial Susceptibilities and Distribution of Resistance Genes for β-Lactams in Streptococcus pneumoniae Isolated in Hamadan.

Authors:  Mohammad Najafi Mosleh; Marzieh Gharibi; Mohammad Yousef Alikhani; Massoud Saidijam; Giti Kalantarian
Journal:  Jundishapur J Microbiol       Date:  2014-10-01       Impact factor: 0.747

9.  Antimicrobial susceptibility and analysis of macrolide resistance genes in Streptococcus pneumoniae isolated in Hamadan.

Authors:  Mohammad Najafi Mosleh; Marzieh Gharibi; Mohammad Yousef Alikhani; Massoud Saidijam; Faezeh Vakhshiteh
Journal:  Iran J Basic Med Sci       Date:  2014-08       Impact factor: 2.699

10.  Changes in capsule and drug resistance of Pneumococci after introduction of PCV7, Japan, 2010-2013.

Authors:  Naoko Chiba; Miyuki Morozumi; Michi Shouji; Takeaki Wajima; Satoshi Iwata; Kimiko Ubukata
Journal:  Emerg Infect Dis       Date:  2014-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.